On June 10, Aratana Therapeutics Chief Executive Officer Steven St. Peter and Chief Financial Officer Craig Tooman presented at the Annual Growth Stock Conference in Chicago. The company highlighted the business development to date and several updates to its ongoing safety and clinical programs that were also presented recently at the American College of Veterinary Internal Medicine Forum (AVCIM) in Nashville. The company s 15-plus product portfolio is progressing with no attrition thus far; we expect a launch of AT-005, for the indication of T-cell lymphoma, in October of this year.
Furthermore, at AVCIM, Aratana s development partner Advaxis (ADXS $3.45) reported on the companies partnered ADXS-cHER2 immunotherapy program. We expect the Aratana to continue executing on their strategic goals and do not expect any additional acquisitions at this point; however, their product portfolio could expand through additional licensing deals. Regarding Aratana s pipeline programs, Grapipant (AT-001), for the indication of osteoarthritis pain in dogs and cats, was well tolerated by dogs over the treatment course of nine months at doses 10 times higher than the anticipated therapeutic dose.
In addition, there were no significant adverse events (AE) and a minimal toxicity profile. The potential market for osteoarthritis in dogs is approximately $260 million, given current market pricing. Capromorelin (AT-002), for appetite stimulation, showed a mean change in appetite score of 79.4%, compared to 22.2% in placebo (p = 0.0251) in dogs.
These increases were also significantly correlated with a percentage change in body weight (r2 = 0.503, p = 0.0054). Lastly, the ADXS-cHER2 therapy for the ongoing study involving the treatment of osteosarcoma in dogs continues to suggest efficacy. The results reported at AVCIM showed 80% of dogs treated (N=15) were still alive (median survival not reached), while the control group animals have all deceased with a median overall survival of 316 days.